These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 16489075

  • 1. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer.
    Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Risch HA, Puopolo M, Yu H.
    Clin Cancer Res; 2006 Feb 15; 12(4):1208-14. PubMed ID: 16489075
    [Abstract] [Full Text] [Related]

  • 2. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
    Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H.
    Cancer Invest; 2008 Mar 15; 26(2):185-92. PubMed ID: 18259951
    [Abstract] [Full Text] [Related]

  • 3. Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer.
    Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Schwartz P, Yu H.
    Gynecol Oncol; 2006 Dec 15; 103(3):990-5. PubMed ID: 16859738
    [Abstract] [Full Text] [Related]

  • 4. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
    Sayer RA, Lancaster JM, Pittman J, Gray J, Whitaker R, Marks JR, Berchuck A.
    Gynecol Oncol; 2005 Feb 15; 96(2):355-61. PubMed ID: 15661221
    [Abstract] [Full Text] [Related]

  • 5. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.
    Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H.
    Cancer Res; 2007 Nov 01; 67(21):10117-22. PubMed ID: 17974952
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Local expression of insulin-like growth factor-I, insulin-like growth factor-I receptor, and estrogen receptor alpha in ovarian cancer.
    An Y, Cai L, Wang Y, Zhu D, Guan Y, Zheng J.
    Onkologie; 2009 Nov 01; 32(11):638-44. PubMed ID: 19887867
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
    Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V.
    Anticancer Res; 2003 Nov 01; 23(5A):3825-35. PubMed ID: 14666684
    [Abstract] [Full Text] [Related]

  • 12. [The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer].
    Yan XJ, Tian Y, Wang C, Wang XL, Di JM, Cheng JX.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul 01; 40(4):639-43. PubMed ID: 19764562
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM.
    Cancer Res; 1999 May 01; 59(9):2203-9. PubMed ID: 10232609
    [Abstract] [Full Text] [Related]

  • 15. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer.
    Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP.
    Clin Cancer Res; 2007 Mar 01; 13(5):1438-44. PubMed ID: 17332286
    [Abstract] [Full Text] [Related]

  • 16. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.
    Han JY, Choi BG, Choi JY, Lee SY, Ju SY.
    Lung Cancer; 2006 Nov 01; 54(2):227-34. PubMed ID: 16935391
    [Abstract] [Full Text] [Related]

  • 17. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.
    Paju A, Vartiainen J, Haglund C, Itkonen O, von Boguslawski K, Leminen A, Wahlström T, Stenman UH.
    Clin Cancer Res; 2004 Jul 15; 10(14):4761-8. PubMed ID: 15269150
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S, Vitelli G, Mirabelli R, Digiesu G, Giannarelli D, Cuneo A, Ribatti D, Vacca A.
    Eur J Haematol; 2006 Jan 15; 76(1):51-7. PubMed ID: 16343271
    [Abstract] [Full Text] [Related]

  • 20. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ, Ohama K.
    Oncol Rep; 2004 Jun 15; 11(6):1153-9. PubMed ID: 15138549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.